Background: Esophagectomy is a complex operation and is associated with significant morbidity and mortality. In an attempt to lower morbidity, we have adopted a minimally invasive approach to esophagectomy. Objectives: Our primary objective was to evaluate the outcomes of minimally invasive esophagectomy (MIE) in a large group of patients. Our secondary objective was to compare the modified McKeown minimally invasive approach (videothoracoscopic surgery, laparoscopy, neck anastomosis [MIE-neck]) with our current approach, a modified Ivor Lewis approach (laparoscopy, videothoracoscopic surgery, chest anastomosis [MIE-chest]). Methods: We reviewed 1033 consecutive patients undergoing MIE. Elective operation was performed on 1011 patients; 22 patients with nonelective operations were excluded. Patients were stratified by surgical approach and perioperative outcomes analyzed. The primary endpoint studied was 30-day mortality. Results: The MIE-neck was performed in 481 (48%) and MIE-Ivor Lewis in 530 (52%). Patients undergoing MIE-Ivor Lewis were operated in the current era. The median number of lymph nodes resected was 21. The operative mortality was 1.68%. Median length of stay (8 days) and ICU stay (2 days) were similar between the 2 approaches. Mortality rate was 0.9%, and recurrent nerve injury was less frequent in the Ivor Lewis MIE group (P < 0.001). Conclusions: MIE in our center resulted in acceptable lymph node resection, postoperative outcomes, and low mortality using either an MIE-neck or an MIE-chest approach. The MIE Ivor Lewis approach was associated with reduced recurrent laryngeal nerve injury and mortality of 0.9% and is now our preferred approach. Minimally invasive esophagectomy can be performed safely, with good results in an experienced center.
T he incidence of esophageal cancer has been increasing over the past 3 decades. 1, 2 In the United States and the western world, this profound increase has been due to an increase in the incidence of adenocarcinoma of the esophagus. This major epidemiologic shift is thought to be related to gastroesophageal reflux disease, obesity, and Barrett's esophagus, the dominant risk factors for esophageal adenocarcinoma. 1, 2 Outcomes after diagnosis of esophageal cancer are suboptimal, with a 5-year survival rate of 15% to 25%, although an improvement in survival, associated with early-stage disease, was seen in recent surgical series. [1] [2] [3] Esophagectomy is a primary curative modality for localized esophageal cancer. However, esophagectomy is a complex operation and the mortality of esophageal resection has been significant. Birkmeyer and colleagues 4 reported that the mortality of esophagectomy ranged from 8% to 23% in the United States and depended on the hospital volume. The morbidity associated with esophagectomy has raised concerns about the procedure and referral for esophagectomy. This is becoming increasingly important with an emerging interest in nonsurgical options for early-stage disease, such as endomucosal resection, endoscopic ablative strategies such as photodynamic therapy, and for more advanced disease, definitive chemoradiation. 3 Frequently, due consideration for surgical resection may not be given because of concerns with regard to the morbidity of open esophagectomy. If we can safely accomplish esophageal resection with a less-invasive approach, this could provide an effective treatment modality-esophagectomy with lesser morbidity for both early-stage disease and for patients with more locally advanced stages, who might be candidates for a lower morbidity resection option. In an effort to decrease the morbidity associated with esophagectomy, we and others have adopted a minimally invasive approach to esophageal resection. [5] [6] [7] [8] Over the last 2 decades, minimally invasive approaches have been described for the performance of several surgical procedures for the treatment of both benign and malignant diseases. [9] [10] [11] [12] With the introduction of laparoscopic fundoplication by Dallemagne and coworkers 13 in 1991, several esophageal diseases, such as achalasia, paraesophageal hernias, and redo antireflux surgery, have been treated with minimally invasive approaches. [9] [10] [11] 13 A minimally invasive approach to esophagectomy was originally described by Cuschieri et al 14 and DePaula et al. 15 Since then, MIE has been performed with increasing frequency. [5] [6] [7] [8] 16, 17 We had originally adopted a modified McKeown 3-incision MIE and more recently transitioned to a minimally invasive Ivor Lewis approach. 5, 7 The primary objective of this study was to evaluate the outcomes after MIE with a focus on perioperative outcomes in a large group of patients. Our secondary objective was to do a preliminary comparison of the results between the modified McKeown MIE and our current approach, a modified Ivor Lewis MIE.
PATIENTS AND METHODS

Patient Selection
All patients undergoing planned MIE at University of Pittsburgh Medical Center from August 1, 1996 , to March 31, 2011, were reviewed (n = 1033), and patients undergoing nonelective operations (n = 22) were excluded. Patients undergoing a planned hybrid procedure (ie, planned thoracotomy with laparoscopy [n = 79] or planned laparotomy with videothoracoscopic surgery [VATS] [n = 21]) were excluded. Patients undergoing esophagectomy as a component of pharyngolaryngectomy were excluded (n = 2). Patients (n = 1011) were stratified into 2 groups on the basis of the approach and location of the anastomosis (McKeown type 3-incision [MIE-neck], n = 481;
Operative Approach
Our approach to MIE has been refined over the study time period and both techniques have been described in detail elsewhere. 5, 7 Briefly, we defined modifications of the McKeown approach as MIE-neck, consisting of either (1) laparoscopic esophagectomy with gastric-pull through and cervical anastomosis (n = 19) or (2) thoracoscopic esophageal mobilization and intrathoracic lymphadenectomy followed by laparoscopic gastric mobilization and formation of the gastric conduit (Fig. 1) , lymph node dissection, and cervical anastomosis. In most cases, a staging laparoscopy was performed in the same setting or as a separate procedure to ensure resectability. We defined modifications of the Ivor Lewis technique as MIE-chest, consisting of laparoscopic gastric mobilization and formation of a gastric conduit ( Fig. 1) and lymph node dissection, followed by thoracoscopic esophageal mobilization and intrathoracic lymphadenectomy. An intrathoracic anastomosis was performed thoracoscopically through a non-rib-spreading, mini-access incision (4 to 5 cm), typically using an end-to-end anastomotic (EEA) stapler (Fig. 2) . Most of the patients also had placement of a feeding jejunostomy tube (>95%) and a pyloric drainage procedure (>85%).
Esophagectomy Outcomes
Retrospective chart review was performed using a standardized outcome protocol and data were entered into a surgical outcomes database. Patient demographics, preoperative symptoms, laboratory and radiographic studies, operative details, and tumor-specific variables were recorded. Staging was performed according to the American Joint Committee on Cancer sixth edition criteria. 18 Surgical outcomes were abstracted, including postoperative length of stay, postoperative morbidity, and operative mortality. The primary endpoint of the study was operative (total 30-day) mortality.
Statistical Analysis
Descriptive statistics were summarized with frequencies and percentages for categorical variables and median with interquartile range for continuous variables for the entire cohort and then stratified by MIE approach (MIE-neck vs MIE-chest). Chi-Square, Fischer exact, and Student t tests, accounting for unequal variance, were used FIGURE 1. Schematic representation of construction of the gastric conduit. Reproduced with permission from the UPMC Heart, Lung and Esophageal Surgery Institute, University of Pittsburgh Medical Center, Pittsburgh, PA. to describe differences between groups. Survival after MIE was estimated by pathologic stage using the Kaplan-Meier method. Statistical analysis was performed using STATA SE 10.0 Corp software.
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RESULTS
Patient Demographics and Comorbid Conditions
The majority of patients were older than 55 years (75%), male (80%), white (97%), and had malignant disease as the indication for esophagectomy (960/1011, 95%). These demographic characteristics were similar between the 2 operative approaches (Table 1) .
Dysphagia was the most common indication for endoscopic evaluation in patients undergoing esophagectomy for malignant disease (n = 480, 51%). Another 26% of patients (n = 245) were diagnosed after being referred for screening endoscopy for long-standing or medically recalcitrant gastroesophageal reflux disease or during subsequent surveillance for Barrett's esophagus. The remaining patients presented with occult or overt bleeding, odynophagia, epigastric pain, or as incidental findings while being evaluated for other purposes. Induction chemotherapy and/or radiation therapy was administered in 31% of patients with malignant disease.
Technical Details of MIE and Changes in Approach
Over Time Hand-sewn anastomosis was performed in 21% of the MIE-neck group (n = 106) and 1% of the MIE-chest group. Stapled anastomosis, with either an EEA or a gastrointestinal anastomosis stapler, was the preferred approach in the neck group. An EEA stapler was used almost exclusively (99%) in the Ivor Lewis MIE group (P < 0.001) and the size of the EEA stapler used was most commonly a 28-mm EEA. A 25-mm EEA stapler was used significantly less frequently (P < 0.001). The gastric conduit was placed in the esophageal bed in almost all patients. In 6 patients with squamous cell tumors that were abutting the aorta or the airway, the gastric conduit was placed substernally to facilitate postoperative radiation to the tumor bed; anastomosis was performed in the neck in these patients. The frequency of conversion to an open operation remained stable with either approach over the period of study (45/1011, 4.5%). The most common reasons to electively convert the thoracoscopic portion of the procedure to an open approach were adhesions (n = 4), persistent bleeding (n = 6), and tumor bulkiness/adherence or a need to better assess the tumor margins (n = 8). Similarly, the most common reasons for conversion of the laparoscopic portion of the procedure to an open approach were adhesions (n = 10), inadequate Copyright © 2012 Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
conduit length/need for more mobilization (n = 2), and tumor bulkiness/adherence or a need to better assess the tumor margins (n = 5). The rate of conversion was similar between the 2 groups (P = 0.27). Emergent open conversion for bleeding occurred rarely.
Postoperative Adverse Events
There were no intraoperative mortalities. The total 30-day (both in-hospital and out-of-hospital) operative mortality was 1.68% (17/1011). This was lower in the Ivor Lewis MIE group at 0.9% (5/530) but did not reach statistical significance when compared with the McKeown-type MIE-neck group (2.5%, 12/481) ( Table 3) . Of the 17 deaths within 30 days, 16 occurred in-hospital before discharge. There was one patient who was discharged after esophagectomy, and death occurred after discharge but within 30 days. There were 11 additional deaths that occurred in-hospital beyond 30 days; the combined total 30-day and in-hospital mortality for the entire cohort was 2.8% (28/1011) (1.7% in the MIE-Ivor Lewis group and 3.95% in the MIE-neck group).
Major unanticipated intraoperative events, including bleeding (1%), need for splenectomy (0.2%), and myocardial infarction (1%), did not differ significantly between groups. The morbidity is summarized in Table 3 . The overall incidence of postoperative adverse events did not differ between the groups. However, the Ivor Lewis MIE group was significantly less likely to experience vocal cord paresis/paralysis (1%) (P < 0.001).
Pathologic Findings and Adequacy of Cancer Resection
Adenocarcinoma and nodal metastasis were present significantly more frequently in the Ivor Lewis MIE patients (P < 0.05). The R0 resection rate was 98%, with negative margins on final pathologic review. The median number of lymph nodes resected was 21 and was slightly higher in the MIE-chest group; this may be due to better lymph node dissection with increasing surgeon experience. These are summarized in Table 4 .
The median follow-up was 20 months. The overall survival rate at 1 year stratified by pathologic stage at esophagectomy was 86% (stage 0), 89% (stage 1), 80% (stage IIa), 76% (stage IIb), 63% (stage III), and 44% (stage IV). Overall survival for cancer patients treated with MIE without induction therapy is presented in Figure 3 .
DISCUSSION
This study of 1011 patients who underwent MIE represents the largest series to date. This experience has demonstrated that MIE can be performed safely with an overall operative mortality of 1.68%, a median ICU stay of 2 days, and a median hospital stay of 8 days. The morbidity of the procedure was acceptable and similar to or better than most published series of open esophagectomy. In our preliminary comparison of outcomes between the MIE-neck and MIE-chest groups, median length of ICU and hospital stay, overall morbidity, and operative mortality seemed to be similar between the 2 approaches. The 30-day mortality was 0.9% in the MIE Ivor Lewis group and 2.5% in the MIE-Neck group. The incidence of recurrent laryngeal nerve (RLN) injury was significantly lower in the Ivor Lewis MIE-chest group (1%) than in the MIE-Neck group (P < 0.001).
Approaches to Esophagectomy
The optimal approach to esophagectomy, regardless of whether the resection is performed in an open fashion or with minimally invasive techniques, is controversial. The classical open approaches for esophageal resection include a transhiatal resection and transthoracic approaches, such as Ivor Lewis esophagectomy, "3 incision" McKeown-type esophagectomy, and resection with a left thoracotomy or left thoracoabdominal approach. [20] [21] [22] [23] [24] [25] [26] Each approach has advantages, and there are very few randomized studies comparing these approaches. A large randomized study of 220 patients comparing transthoracic esophagectomy (TTE) and transhiatal esophagectomy (THE) was reported by Hulscher and colleagues. 27 Patients who underwent THE had a shorter duration of surgery, less blood loss, and less morbidity; however, there were no differences in perioperative mortality. Significantly, more lymph nodes were resected in patients who underwent TTE. There was a trend toward an improved 5-year disease-free survival and overall survival in the TTE group, although this did not reach statistical significance. On longer follow-up, patients with limited nodal metastases seem to have a survival benefit. Although the open transthoracic approach showed a trend toward better survival, and better lymphadenectomy, there was an increase in morbidity with this approach in comparison with THE.
The extent of lymph node dissection required for patients with esophageal cancer also remains controversial.
28-30 However, adequate lymph node sampling is required for accurate staging. 29 One of the potential advantages of the transthoracic approach is better exposure and improved lymph node dissection in the mediastinum. In our current series, the median number of lymph nodes that were removed was 21, which is comparable with other open series. Similarly, the rate of complete resection with negative margins in 98% of patients in the current series is comparable with other open series of esophagectomy. However, long-term oncologic efficacy of MIE needs to be evaluated. We currently prefer an Ivor Lewis MIE with a 2-field approach for the lymph node dissection for the treatment of esophageal cancer.
In terms of optimal location for the anastomosis, the potential benefits of a cervical anastomosis are a more proximal resection margin and the potentially lower morbidity associated with a cervical anastomotic leak. An intrathoracic location potentially has reduced tension at the anastomosis, the ability to remove some of the potentially ischemic gastric tip, a lower rate of anastomotic leak, and a lower incidence of RLN injury. 30 However, a randomized trial did not show significant differences between these approaches. 31 We found a decrease in recurrent nerve injury noted when using the Ivor Lewis approach with an intrathoracic anastomosis compared with the 3-incision McKeown approach with a neck anastomosis. This finding is similar to that reported in one meta-analysis of more than 5000 patients comparing TTE and THE. An increase in RLN injuries and leak were noted with a transhiatal approach with a neck anastomosis.
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There are a few series reporting excellent outcomes with an open esophagectomy. [20] [21] [22] [23] [24] [25] [26] [27] [28] 33 In one of the largest series of 3-incision esophagectomy, Swanson and colleagues 23 reported an anastomotic leak in 8% and an operative mortality of 3.6%. In another large study with an Ivor Lewis approach, Visbal and colleagues 24 reported an operative mortality of 1.4%, RLN injury in 0.9%, and a median length of stay in the hospital of 11 days, which are similar to our study.
We initially performed the MIE with a transhiatal approach. However, it became apparent that visualization higher up in the mediastinum was difficult. In addition, complete mediastinal lymph node dissection could not be performed. This led to us adopting the 3-incision McKeown-type approach to perform the MIE. 5 Our approach has since evolved from this modified McKeown MIE to a minimally invasive Ivor Lewis approach. The shift was prompted by the changing demographics of patients with esophageal cancer and an effort to reduce the morbidity associated with RLN dysfunction. Since the vast majority of tumors that we now encounter are located in the distal esophagus and gastroesophageal junction, the proximal esophageal resection margin is usually adequate with a high intrathoracic anastomosis. Furthermore, in the presence of distal tumor extension onto the gastric cardia, an intrathoracic location of the anastomosis potentially allows for a more extensive resection of the stomach and wider tumor margins distally. These factors, in combination with the minimal neck experience obtained during general surgical and thoracic surgical training, led to a greater degree of comfort in performing and teaching this operation as an Ivor Lewis MIE.
The use of minimally invasive approaches to esophagectomy is increasing and improved outcomes have been reported by other investigators after MIE. 6, 8, 17 In our recent review of the medical literature using the US National Library of Medicine service, PubMed, to identify MIE-related reports, we noted a minimal number of publications on this topic less than a decade ago, and this has risen exponentially over the last few years (Fig. 4) . In a recent study evaluating the trends in utilization and outcomes of MIE and open esophagectomy, Lazzarino et al 17 reported an exponential increase in the performance of MIE in England and there was a trend toward better 1-year survival in patients undergoing MIE. 17 In a systematic review of more than 1100 patients evaluating MIE and open esophagectomy, MIE was associated with decreased morbidity and a shorter hospital stay compared with open esophagectomy.
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Reducing the Risks of Surgery
There are several factors that are associated with a decrease in the risks of esophagectomy. These include hospital volume with mortality being significantly lower in high-volume centers. 4 Orringer et al, 35 in an important study of THE, reported the results in more than 2000 patients with the operative mortality rate that had steadily decreased with increasing hospital volume and surgeon experience from 10% to 1%. Similarly, these investigators demonstrated that complications, such as RLN injury, decreased with increased volume from 32% in the period of 1978 to 1982 to 1% to 2% in current era. These data point to the steep learning curve that general-and thoracic-trained surgeons will likely experience if the neck approach is chosen. Few surgeons or centers are likely to ever reach the excellent results of the neck approach in Orringer's more recent series. Esophagectomy is a complex and technically challenging operation, and other factors that have an impact on outcomes include surgeon volume and specialty training of the surgeon. In addition, the daily participation of critical care specialists in the care of the patient is associated with improved outcomes.
36-37 All of these factors may have contributed to our successful outcomes after MIE.
Strengths and Limitations
The strengths of this study are that it is the largest to date investigating MIE, with more than 1000 patients, and that it is one of the first comparisons of the Ivor Lewis and modified McKeown MIE procedures. There are several confounding factors, however, in this retrospective analysis, which include differences in patient characteristics, the performance of the Ivor Lewis MIE in the more recent era, increasing surgeon experience, expertise in postoperative management and critical care, and other factors in evolution over time.
Further work is needed to analyze the factors contributing to differences in outcomes. The other limitations of this study include those that are common to retrospective studies, including selection bias. In addition, longer follow-up is required to fully evaluate the oncologic results of MIE.
Future Directions
Recently, the preliminary results of a phase II multiinstitutional study (Eastern Cooperative Oncology Group, ECOG 2202) to evaluate the results of MIE in a multi-institutional setting were reported. 6 In this multi-center cooperative group trial, we acted as the principal investigator center, and a total of 106 patients were enrolled. Morbidity was acceptable and the mortality was 2%. The long-term results of this trial are awaited. In addition, a randomized study, coordinated elsewhere, comparing MIE with open esophagectomy has also been initiated.
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CONCLUSIONS
In this largest series to date of MIE, we have shown that MIE is safe, with low mortality, acceptable morbidity, and a short length of stay. It must be noted that these results were obtained in a center with significant open and minimally invasive experience in esophageal surgery. Our current approach in patients with resectable esophageal cancer is a minimally invasive Ivor Lewis esophagectomy with a 2-field lymph node dissection. The potential advantages of this approach include the potential for improved lymph node dissection in the mediastinum and potential for lower rates of anastomotic and RLN complications. Minimally invasive esophagectomy can be performed safely with good results in an experienced center. 23 
DISCUSSANTS D. Sugarbaker (Boston, MA):
You and your colleagues are to be congratulated for developing this technique and teaching it to so many of us. You report a low overall mortality of 1.9%, which is among the lowest reported series done, either open or minimally invasively. I have 4 questions for you.
First, you reported the 30-day operative mortality, which can often underestimate the overall mortality in this operation because some patients can be managed postoperative in the ICU almost indefinitely but not have a good outcome. Do you have in-hospital mortality figures or 90-day mortality values? For that matter, what percentage of patients, overall, are discharged home versus to a rehabilitation center.
Second, your leak rate is similar in both the neck and chest anastomosis; about 5%. Have you noticed a difference in patients with a chest leak versus a neck leak? Did they require more reoperative surgery? Did you see an increased length of hospitalization?
Third, the recent Cross study presented at American Society of Clinical Oncology in 2010 demonstrated a significant survival advantage in stage 2 and 3 surgically resected patients who received neoadjuvant chemoradiotherapy. Your 2003 paper notes that 51% received either neoadjuvant chemotherapy alone or chemoradiotherapy, although only 36% of these patients had stage 3 disease.
This updated paper notes an increased trend toward more locally advanced disease with 45% of patients experiencing T3 disease in the MIE chest group, yet only 29% of patients got neoadjuvant treatment. Has your utilization of neoadjuvant therapy decreased over the years for advanced disease? If so, why? Do patients who receive upfront therapy receive chemotherapy alone, or chemo and radiation therapy combined? Do you think this is related to the 4% local recurrence rate that you report?
Finally, you perform a pyloric drainage procedure, a pyloroplasty in 86% of patients. What is your rate of dumping syndrome in these patients, as this question has long haunted esophageal surgeons, drainage procedure or none? Have your compared outcomes with the 14% of patients who did not receive a pyloric procedure shown you any light in this particular area?
Response from J.D. Luketich:
The 30-day mortality for the entire group was 1.7%, and this increased to 2.8% if we include both the combined total 30-day and overall in-house mortality. In the most recent 500 MIEs, those performed by the Ivor Lewis approach, there was a slight improvement in outcomes, and the 30-day mortality was 0.9%, with the combined total 30-day and in-house mortality of 1.7%. We elaborated on this in the article in terms of the other details you asked.
Regarding those going home or to a rehabilitation center first, we do not have that information on the entire series. Looking at subsets where that question has been answered more recently, it certainly looks like 90% are going home. However, an important 10%, or 8% if you subtract, say, that 1% or 2% mortality, are clearly not making it home immediately. We do not have enough data to comment on the ultimate disposition in this.
We do have some encouraging data on quality of life after MIE, although we have not analyzed this in the entire cohort of patients. We studied the SF-36 Short Form Health Survey at 90 days in a large subset of patients that was collected more recently, and certainly, the overall quality of life after MIE by 3 months does seem to match for both the physical and psychological parts of the 36-Item Short Form Health Survey, to age-adjusted normals. So, it seems pretty clear that by 90 days, the majority of patients bounce back. A recent study from England similarly showed a rapid restoration of QOL with an MIE.
As for leaks, less than half of those that occurred in the chest have required reoperation. In most cases, we have been able to avoid reoperation if the leak drains primarily to the drain. For those not satisfactorily drained, we were able to manage many with a VATS decortication and repair the fistula over a t-tube or just place additional drains. Generally, we have seen less chronic problems with stricture formation after Ivor Lewis chest anastomosis compared with a neck anastomosis. Part of this may be because we now use a 28-mm EEA routinely in the chest for the anastomosis. In either location, a leak invariably adds a couple of days to the hospital stay, even if easily managed nonoperatively.
In the neck, we had been doing either a hand-sewn, side-toside stapling or using a 25-mm EEA. In our experience with the neck anastomosis, we seemed to have more problems with stricture complications that were a little bit more resistant to dilation. The chest anastomosis using the 28-mm EEA seems to be a little easier to manage for us.
Regarding the Cross study, the mature and final results are eagerly awaited. In this randomized study of neoadjuvant chemoradiation and surgery versus surgery, the preliminary results seem favorable to neoadjuvant therapy, and in subset analysis, this benefit Copyright © 2012 Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited. appeared to be primarily in those with squamous cell carcinoma. Interestingly, in the preliminary presentation, subset analysis did not show a significant difference in hazard ratios for adenocarcinoma, that is, there was no significant benefit in adenocarcinoma patients, who comprised 74% of the patients in the study. Adenocarcinoma is also the predominant histology we encounter in our population. In addition, approximately 14% randomized to surgery alone did not undergo resection at all and I am not sure what treatment they received. However, these are all the preliminary results. As many other trials have come and gone that have been initially encouraging when the shortterm data were presented, it is not yet in manuscript form, and the long-term outcomes are anxiously awaited, but it does not mean we have given up on neoadjuvant treatment. For every positive study out there, there is another one that has been negative and the overall best chemotherapy or the best approach, I think, has yet to be determined.
We do use neoadjuvant chemotherapy for most T3 tumors, and T2 if nodal burden is present. Overall, many of the patients come to us having already completed chemotherapy and how that pans out from study to study or year to year is a little bit different. Those with very limited nodal disease of a single node or 1 to 2 nodes, or perhaps T3N0 by best assessment, might receive R0 resection followed by postoperative chemotherapy. Those who have more significant nodal disease but seem resectable would generally get chemotherapy alone preoperatively. We are reserving chemoradiation combination therapy for more advanced disease where we believe we need a significant local downstaging to consider resection.
We have not been routinely using preoperative chemoradiation therapy, rather we have been more in favor of aggressive staging up front. If we think there is nodal disease, but looks generally resectable at presentation, we would give neoadjuvant chemotherapy only. We studied this approach in about 75 patients with what seemed to be resectable locally advanced esophageal cancer, most of the patients with N1 disease. In this study, all patients received 3 cycles of chemotherapy upfront, followed by esophagectomy and 2-field lymph node dissection. The overall survival at 40 months' follow-up was close to 40% and those with local recurrence only was limited to 4%. Most recurrences were distal and primarily to the liver. With these results in node positive patients using neoadjuvant chemotherapy alone followed by surgery and adjuvant therapy, we were pretty convinced we would not do better by adding radiation and could increase our toxicity and complication rate.
I think if you are performing less of a node dissection, transhiatal, or whatever your approach might be, and your local recurrence rates are high, you have to consider routine radiation as part of your upfront treatment. Also, if you are faced with a patient with bulky disease with whom you want to try to achieve your best upfront downstaging, we still use chemotherapy and radiation in that setting. The primary distinction is that for patients who seem to be unresectable upfront, or marginally resectable, we would prefer a chemoradiation approach either as definitive therapy or in ideal patients as neoadjuvant therapy.
Regarding your last comment about pyloroplasty, I do not have a comparison of the 14% who did not get the pyloroplasty compared with those who did, but that would be an interesting subset to analyze.
J. Hunter (Portland, OR):
We started with what we call the 3-field approach, as did you, and moved to the thoracic-only, (the MIE Ivor Lewis approach) and then returned to the 3-field for the reasons that I think Dr. Sugarbaker alluded to. Although the leak rates were equivalent, the severity of the leaks were worse when they occurred intrathoracically than when they occurred in the neck and I think the recurrent laryngeal nerve injury is a technical problem that can largely be avoided by understanding the anatomy of the neck and by performing extremely careful dissection under loupe magnification.
So I really just have 2 questions. First, what about the midesophageal cancers, where obtaining a negative proximal margin can be a bit more problematic with the Ivor Lewis approach? Do you still use the 3-field esophagectomy for those patients?
Second, some of your colleagues in thoracic surgery have become enamored with robotic resection, especially for lymphadenectomy. Have you tried this? Do you think it offers any advantage to a high-volume thoracic VATS surgeon?
Response from J.D. Luketich:
Regarding the midesophageal squamous cancers, we are not seeing many in our referral pattern. However, if the tumor is high, they would either undergo consideration for definitive chemoradiation with no surgery or if it is high but potentially resectable only by a McKeown 3-incision approach, then yes, we would do this. However, we have found that during the VATS part of an Ivor Lewis esophagectomy, we can go quite high on the esophagus, up toward the thoracic inlet, and in the majority of even mid esophageal squamous cancers we can still achieve a negative margin. It really depends on exactly where that tumor is and how comfortable you are getting your margin, but if you need to, then go to the neck to get a negative margin, via the McKeown approach.
Regarding your comment about recurrent laryngeal nerve injuries, I think just when you get an attending or a group of residents comfortable with this, you start over with a new group, and while I appreciate your comments, when I look at Dr. Orringer's experience, which is vast and essentially never matched by a single individual, he has noted a very low recurrent nerve injury rate. However, when you look back at his first 500 or even 1000 cases, there was a much higher leak rate and recurrent nerve injury rate. So, if you think your residents are getting a significant neck surgical experience on other rotations and you have enough volume and are confident that your attendings can teach the neck approach with a low complication rate, then you may well be able to do this. However, I do think the recurrent nerve injury rate is often understated, poorly studied, and I do not think it's easy to master. Also, in the vast majority of gastroesophageal junction cancers we are seeing, there is no oncologic reason to perform a neck anastomosis. We are also convinced the leak rate in the chest will be our lowest compared with our neck anastomosis group and as we gain more VATS experience with the Ivor Lewis anastomosis, our leak rate continues to decline and in most cases we do not need to reoperate, if it is well drained.
Your next question was about robotics. Benny Weksler in our group is leading the effort for our thoracic group with robotics. He has done more than 250 robotic thoracic cases but only 4 MIEs. In one, there was a very significant complication and death from an airway injury. We went back to the drawing board to gain more experience and may reconsider this. Right now we are not doing MIEs robotically. In my opinion, there is no advantage to this approach and it has the potential for significant risks and no doubt, higher costs. That is my own opinion.
W. Holcomb (Kansas City, MO):
A quick question on the methodology. Could you explain which patients received which operation? That is, was the operation based on the patient or was it based on surgeon's preference? many years at UPMC, at Pittsburgh, PA. So we were comfortable with that operation.
As the tumors we see have become more and more dominant lower third adenocarcinomas, we realized that we really had a choice. You could go perform the anastomosis in the neck, but there was no oncologic compromise by performing a high intrathoracic anastomosis. Therefore, in combination with the learning curve and the experience of the residents we are seeing today, and the experience of my attendings today, I felt that if I did not need to go to the neck and I could do the chest operation with lower morbidity, so it was an evolution over time. With the predominance of distal esophageal and gastroesophageal junction tumors, we prefer the Ivor Lewis approach now and we are probably going to stick with it. We do not have randomized data. Response from J.D. Luketich:
For the margins, we freeze them always, and the first thing we do at the beginning of each operation is an on-the-table esophagogastroscopy. We always scope first in the operating room. It may change your approach although most of our patients have endoscopic ultrasound (EUS) upfront and we do give a lot of consideration to the preoperative EUS and CT. However, subtle inaccuracies or missed important findings such as Barrett's at the proximal margin or even gastric tumor extension at the distal margin are best assessed by the surgeon the day of the planned operation. Certainly proximal extension of Barrett's can even be a problem on occasion even if you do the anastomosis in the neck, so you have to watch for it. I think you have to be prepared to go higher, if indicated.
One thing we have found is that our anastomotic levels are actually not very different at all whether we do a neck anastomosis or do a high intrathoracic VATS EEA anastomosis. When we scope patients in follow-up, the anastomosis tends to be right around 20 cm from the incisors with transhiatal, and similar with Ivor Lewis. Certainly, the VATS approach allows one to get a great angle and view of the high intrathoracic esophagus, and if you mobilize the esophagus into the inlet, you can really get the esophagus top to pull down and get quite a high anastomosis.
Regarding the difference between an open and minimally invasive approach and specimen retrieval, there is not a lot of difference. Regarding open experience in general, my group and myself included still do at least 10% of all esophagectomies open for trauma, perforations, redo settings, lye ingestions, bulky tumors, etc. In general, for the Ivor Lewis, we make a 5-cm incision and bring the specimen out through this incision using a wound protector. Most of these tumors are obviously not growing out of the esophagus so we actually use the wound protector to primarily to prevent spillage of saliva in the wound and other things, to keep it clean, not for the tumor spillage that we are worried about, because, as you know, during a transhiatal, there is a lot of sloshing around of hands and tumor.
So, oncologically, I believe an MIE by McKeown or Ivor Lewis approach is sound. I do not think it makes a big difference, but occasionally, there will be a big, bulky tumor. You have the question, should you be there? If there is a big, bulky tumor, I would consider an access incision in the abdomen, place a large endoscopic specimen bag in, and place the specimen in there, and take the specimen out that way. So, yes, occasionally, we choose an open operation.
R. Greene (Charlotte, NC):
I have a question about timing of the resection after neoadjuvant therapy. It has been shown in rectal cancer management that the longer you wait, the more opportunity there is for complete pathologic response. What is your recommendation for the optimal time for waiting after neoadjuvant therapy?
Response from J.D. Luketich:
A lot of it is a gestalt of how the patient looks; that is, what's their performance status? A minimum of 4 weeks, but it is not unusual to wait 6 weeks or longer depending primarily on performance status of the patient.
